LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 26

Search options

  1. Article ; Online: The Impact of the Cancer Moonshot on Cardio-Oncology Science.

    Minasian, Lori M / Adhikari, Bishow B / Dimond, Eileen P / Shelburne, Nonniekaye / Shi, Scarlet / Desvigne-Nickens, Patrice

    JACC. CardioOncology

    2022  Volume 4, Issue 3, Page(s) 413–416

    Language English
    Publishing date 2022-09-20
    Publishing country United States
    Document type Editorial
    ISSN 2666-0873
    ISSN (online) 2666-0873
    DOI 10.1016/j.jaccao.2022.08.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Cancer-related emergency and urgent care: expanding the research agenda.

    Shelburne, Nonniekaye / Simonds, Naoko Ishibe / Jensen, Roxanne E / Brown, Jeremy

    Emergency Cancer Care

    2022  Volume 1, Issue 1, Page(s) 4

    Abstract: Purpose of review: Cancer-related emergency department (ED) visits often result in higher hospital admission rates than non-cancer visits. It has been estimated many of these costly hospital admissions can be prevented, yet urgent care clinics and EDs ... ...

    Abstract Purpose of review: Cancer-related emergency department (ED) visits often result in higher hospital admission rates than non-cancer visits. It has been estimated many of these costly hospital admissions can be prevented, yet urgent care clinics and EDs lack cancer-specific care resources to support the needs of this complex population. Implementing effective approaches across different care settings and populations to minimize ED and urgent care visits improves oncologic complication management, and coordinating follow-up care will be particularly important as the population of cancer patients and survivors continues to increase. The National Cancer Institute (NCI) and the Office of Emergency Care (OECR) convened a workshop in December 2021, "Cancer-related Emergency and Urgent Care: Prevention, Management, and Care Coordination" to highlight progress, knowledge gaps, and research opportunities. This report describes the current landscape of cancer-related urgent and emergency care and includes research recommendations from workshop participants to decrease the risk of oncologic complications, improve their management, and enhance coordination of care.
    Recent findings: Since 2014, NCI and OECR have collaborated to support research in cancer-related emergency care. Workshop participants recommended a number of promising research opportunities, as well as key considerations for designing and conducting research in this area. Opportunities included better characterizing unscheduled care services, identifying those at higher risk for such care, developing care delivery models to minimize unplanned events and enhance their care, recognizing cancer prevention and screening opportunities in the ED, improving management of specific cancer-related presentations, and conducting goals of care conversations.
    Summary: Significant progress has been made over the past 7 years with the creation of the Comprehensive Oncologic Emergency Research Network, broad involvement of the emergency medicine and oncology communities, establishing a proof-of-concept observational study, and NCI and OECR's efforts to support this area of research. However, critical gaps remain.
    Language English
    Publishing date 2022-06-14
    Publishing country England
    Document type Journal Article ; Review
    ISSN 2731-4790
    ISSN (online) 2731-4790
    DOI 10.1186/s44201-022-00005-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Questions About Emergency Department Treatment of Patients With Solid Tumors and Hematological Malignant Neoplasms-Reply.

    Rivera, Donna R / Brown, Jeremy / Shelburne, Nonniekaye

    JAMA oncology

    2018  Volume 4, Issue 5, Page(s) 750–751

    MeSH term(s) Adult ; Emergency Service, Hospital ; Hematologic Neoplasms ; Humans ; Neoplasms
    Language English
    Publishing date 2018-02-28
    Publishing country United States
    Document type Letter ; Comment
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2017.5534
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Mitigating Cardiovascular Dysfunction Across the Cancer Continuum

    Shelburne, Nonniekaye M / Hammer, Marilyn J

    Oncology nursing forum

    2017  Volume 45, Issue 1, Page(s) 15–17

    Abstract: The mechanisms and outcomes of cancer treatment-related cardiovascular dysfunction are complex and influenced by cardiotoxic treatment exposure, preexisting heart disease, and lifestyle factors. Establishing and implementing evidence to prevent, detect, ... ...

    Abstract The mechanisms and outcomes of cancer treatment-related cardiovascular dysfunction are complex and influenced by cardiotoxic treatment exposure, preexisting heart disease, and lifestyle factors. Establishing and implementing evidence to prevent, detect, and manage cancer treatment-related cardiotoxicity requires engagement by the nursing science community.
.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Breast Neoplasms/drug therapy ; Cardiovascular Diseases/drug therapy ; Cardiovascular Diseases/etiology ; Female ; Humans ; Middle Aged ; Risk Factors
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2017-12-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 604886-9
    ISSN 1538-0688 ; 0190-535X ; 1538-0688
    ISSN (online) 1538-0688 ; 0190-535X
    ISSN 1538-0688
    DOI 10.1188/18.ONF.15-17
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Demographic and Health Behavior Factors Associated With Clinical Trial Invitation and Participation in the United States.

    Williams, Courtney P / Senft Everson, Nicole / Shelburne, Nonniekaye / Norton, Wynne E

    JAMA network open

    2021  Volume 4, Issue 9, Page(s) e2127792

    Abstract: Importance: Representative enrollment in clinical trials is critical to ensure equitable and effective translation of research to practice, yet disparities in clinical trial enrollment persist.: Objective: To examine person-level factors associated ... ...

    Abstract Importance: Representative enrollment in clinical trials is critical to ensure equitable and effective translation of research to practice, yet disparities in clinical trial enrollment persist.
    Objective: To examine person-level factors associated with invitation to and participation in clinical trials.
    Design, setting, and participants: This cross-sectional study analyzed responses from 3689 US adults who participated in the nationally representative Health Information National Trends Survey, collected February through June 2020 via mailed questionnaires.
    Exposures: Demographic, clinical, and health behavior-related characteristics.
    Main outcomes and measures: History of invitation to and participation in a clinical trial, primary information sources, trust in information sources, and motives for participation in clinical trials were described. Respondent characteristics are presented as absolute numbers and weighted percentages. Associations between respondent demographic, clinical, and health behavior-related characteristics and clinical trial invitation and participation were estimated using survey-weighted logistic regression models.
    Results: The median (IQR) age of the 3689 respondents was 48 (33-61) years, and most were non-Hispanic White individuals (2063 [59%]; non-Hispanic Black, 452 [10%]; Hispanic, 521 [14%]), had more than a high school degree (2656 [68%]), were employed (1809 [58%]), and had at least 1 medical condition (2535 [61%]). Overall, 439 respondents (9%) had been invited to participate in any clinical trial. Respondents with increased odds of invitation were non-Hispanic Black compared with non-Hispanic White (adjusted odds ratio [aOR], 1.85; 95% CI, 1.13-3.02), had greater than a high school education compared with less than high school education (eg, ≥college degree: aOR, 4.84; 95% CI, 1.89-12.39), were single compared with married or living as married (aOR, 1.68; 95% CI, 1.04-2.73), and had at least 1 medical condition compared to none (eg, 1 medical condition: aOR, 2.25; 95% CI, 1.32-3.82). Respondents residing in rural vs urban areas had 77% decreased odds of invitation to a clinical trial (aOR 0.33; 95% CI 0.17-0.65). Of invited respondents, 199 (47%) participated. Compared with non-Hispanic White respondents, non-Hispanic Black respondents had 72% decreased odds of clinical trial participation (aOR, 0.28; 95% CI, 0.09-0.87). Respondents most frequently reported "health care providers" as the first and most trusted source of clinical trial information (first source: 2297 [59%]; most trusted source: 2597 [70%]). The most frequently reported motives for clinical trials participation were "wanting to get better" (2294 [66%]) and the standard of care not being covered by insurance (1448 [41%]).
    Conclusions and relevance: The findings of this study suggest that invitation to and participation in clinical trials may differ by person-level demographic and clinical characteristics. Strategies toward increasing trial invitation and participation rates across diverse patient populations warrant further research to ensure equitable translation of clinical benefits from research to practice.
    MeSH term(s) Adult ; Aged ; Clinical Trials as Topic ; Cross-Sectional Studies ; Demography/statistics & numerical data ; Ethnicity/statistics & numerical data ; Female ; Health Behavior ; Health Surveys ; Humans ; Male ; Middle Aged ; Research Subjects/psychology ; Research Subjects/statistics & numerical data ; United States
    Language English
    Publishing date 2021-09-01
    Publishing country United States
    Document type Journal Article
    ISSN 2574-3805
    ISSN (online) 2574-3805
    DOI 10.1001/jamanetworkopen.2021.27792
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Spectrum of National Institutes of Health-Funded Research in Cardio-Oncology: A Basic, Clinical, and Observational Science Perspective.

    Adhikari, Bishow B / Shi, Scarlet / Dimond, Eileen P / Shelburne, Nonniekaye / Desvigne-Nickens, Patrice / Minasian, Lori M

    Heart failure clinics

    2022  Volume 18, Issue 3, Page(s) 515–528

    Abstract: Advances in cancer treatments have led to nearly 17 million survivors in the US today. Cardiovascular complications attributed to cancer treatments are the leading cause of morbidity and mortality in cancer survivors. In response, NCI and NHLBI held 2 ... ...

    Abstract Advances in cancer treatments have led to nearly 17 million survivors in the US today. Cardiovascular complications attributed to cancer treatments are the leading cause of morbidity and mortality in cancer survivors. In response, NCI and NHLBI held 2 workshops and issued funding opportunities to strengthen research on cardiotoxicity. A representative portfolio of NIH grants categorizing basic, interventional, and observational projects is presented. Compared with anthracyclines, research on radiation therapy and newer treatments is underrepresented. Multidisciplinary collaborative research that considers the cardiotoxicity stage and optimizes the balance between cardiovascular risk and cancer-treatment benefit might support continued improvements in cancer outcomes.
    MeSH term(s) Anthracyclines/therapeutic use ; Cardiotoxicity/etiology ; Humans ; Medical Oncology ; National Institutes of Health (U.S.) ; Neoplasms/drug therapy ; Neoplasms/therapy ; United States/epidemiology
    Chemical Substances Anthracyclines
    Language English
    Publishing date 2022-06-19
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2212019-1
    ISSN 1551-7136
    ISSN 1551-7136
    DOI 10.1016/j.hfc.2022.01.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Changing Hearts and Minds: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity.

    Shelburne, Nonniekaye / Simonds, Naoko I / Adhikari, Bishow / Alley, Michael / Desvigne-Nickens, Patrice / Dimond, Eileen / Filipski, Kelly / Gallicchio, Lisa / Minasian, Lori

    Current oncology reports

    2019  Volume 21, Issue 1, Page(s) 9

    Abstract: Purpose of review: Cardiovascular effects from cancer treatment remains a leading cause of treatment-associated morbidity and mortality among cancer survivors. The National Cancer Institute and National Heart, Lung, and Blood Institute convened a ... ...

    Abstract Purpose of review: Cardiovascular effects from cancer treatment remains a leading cause of treatment-associated morbidity and mortality among cancer survivors. The National Cancer Institute and National Heart, Lung, and Blood Institute convened a Workshop in June 2018 entitled "Changing Hearts and Minds: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity" to highlight progress, ongoing work, and update scientific priorities since the 2013 Workshop. Here we will describe these advances and provide an overview of the research priorities identified.
    Recent findings: Since 2013, the National Institutes of Health has increased its support of cancer treatment-related cardiotoxicity research through the funding of grants and coordination of internal and external working groups. Workshop participants identified knowledge gaps and recommended over 20 new promising opportunities in basic and clinical cardiotoxicity research. Significant progress on mechanisms, detection, management, and prevention of cardiotoxicity has been made over the past 5 years, yet some critical gaps remain.
    MeSH term(s) Antineoplastic Agents/adverse effects ; Cancer Survivors/statistics & numerical data ; Cardiotoxicity/etiology ; Cardiotoxicity/pathology ; Cardiotoxicity/prevention & control ; Humans ; Neoplasms/drug therapy ; Prognosis
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2019-01-30
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Review
    ZDB-ID 2057359-5
    ISSN 1534-6269 ; 1523-3790
    ISSN (online) 1534-6269
    ISSN 1523-3790
    DOI 10.1007/s11912-019-0751-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Pulmonary Complications of Pediatric Hematopoietic Cell Transplantation. A National Institutes of Health Workshop Summary.

    Tamburro, Robert F / Cooke, Kenneth R / Davies, Stella M / Goldfarb, Samuel / Hagood, James S / Srinivasan, Ashok / Steiner, Marie E / Stokes, Dennis / DiFronzo, Nancy / El-Kassar, Nahed / Shelburne, Nonniekaye / Natarajan, Aruna

    Annals of the American Thoracic Society

    2020  Volume 18, Issue 3, Page(s) 381–394

    Abstract: Approximately 2,500 pediatric hematopoietic cell transplants (HCTs), most of which are allogeneic, are performed annually in the United States for life-threatening malignant and nonmalignant conditions. Although HCT is undertaken with curative intent, ... ...

    Abstract Approximately 2,500 pediatric hematopoietic cell transplants (HCTs), most of which are allogeneic, are performed annually in the United States for life-threatening malignant and nonmalignant conditions. Although HCT is undertaken with curative intent, post-HCT complications limit successful outcomes, with pulmonary dysfunction representing the leading cause of nonrelapse mortality. To better understand, predict, prevent, and/or treat pulmonary complications after HCT, a multidisciplinary group of 33 experts met in a 2-day National Institutes of Health Workshop to identify knowledge gaps and research strategies most likely to improve outcomes. This summary of Workshop deliberations outlines the consensus focus areas for future research.
    MeSH term(s) Child ; Forecasting ; Hematopoietic Stem Cell Transplantation/adverse effects ; Humans ; National Institutes of Health (U.S.) ; Research Design ; Transplantation, Homologous ; United States
    Language English
    Publishing date 2020-10-12
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2717461-X
    ISSN 2325-6621 ; 1943-5665 ; 2325-6621
    ISSN (online) 2325-6621 ; 1943-5665
    ISSN 2325-6621
    DOI 10.1513/AnnalsATS.202001-006OT
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Building internal capacity in pragmatic trials

    Wynne E. Norton / Merrick Zwarenstein / Susan Czajkowski / Elisabeth Kato / Ann O’Mara / Nonniekaye Shelburne / David A. Chambers / Kirsty Loudon

    Trials, Vol 20, Iss 1, Pp 1-

    a workshop for program scientists at the US National Cancer Institute

    2019  Volume 6

    Abstract: Abstract Background Building capacity in research funding organizations to support the conduct of pragmatic clinical trials is an essential component of advancing biomedical and public health research. To date, efforts to increase the ability to design ... ...

    Abstract Abstract Background Building capacity in research funding organizations to support the conduct of pragmatic clinical trials is an essential component of advancing biomedical and public health research. To date, efforts to increase the ability to design and carry out pragmatic trials have largely focused on training researchers. To complement these efforts, we developed an interactive workshop tailored to meet the roles and responsibilities of program scientists at the National Cancer Institute—the leading cancer research funding agency in the USA. The objectives of the workshop were to improve the understanding of pragmatic trials and enhance the capacity to distinguish between elements that make a trial more pragmatic or more explanatory among key programmatic staff. To our knowledge, this is the first reported description of such a workshop. Main body The workshop was developed to meet the needs of program scientists as researchers and stewards of research funds, which often includes promoting scientific initiatives, advising prospective applicants, collaborating with grantees, and creating training programs. The workshop consisted of presentations from researchers with expertise in the design and interpretation of trials across the explanatory-pragmatic continuum. Presentations were followed by interactive, small-group exercises to solidify participants’ understanding of the purpose and conduct of these trials, which were tailored to attendees’ areas of expertise across the cancer control continuum and designed to reflect their scope of work as program scientists at NCI. A total of 29 program scientists from the Division of Cancer Control and Population Sciences and the Division of Cancer Prevention participated; 19 completed a post-workshop evaluation. Attendees were very enthusiastic about the workshop: they reported improved knowledge, significant relevance of the material to their work, and increased interest in pragmatic trials across the cancer control continuum. Conclusion Training program scientists ...
    Keywords Pragmatic trials ; Explanatory trials ; Cancer prevention and control ; Cancer screening ; Cancer care delivery research ; Cancer behavioral research ; Medicine (General) ; R5-920
    Subject code 027
    Language English
    Publishing date 2019-12-01T00:00:00Z
    Publisher BMC
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  10. Article ; Online: Building internal capacity in pragmatic trials: a workshop for program scientists at the US National Cancer Institute.

    Norton, Wynne E / Zwarenstein, Merrick / Czajkowski, Susan / Kato, Elisabeth / O'Mara, Ann / Shelburne, Nonniekaye / Chambers, David A / Loudon, Kirsty

    Trials

    2019  Volume 20, Issue 1, Page(s) 779

    Abstract: Background: Building capacity in research funding organizations to support the conduct of pragmatic clinical trials is an essential component of advancing biomedical and public health research. To date, efforts to increase the ability to design and ... ...

    Abstract Background: Building capacity in research funding organizations to support the conduct of pragmatic clinical trials is an essential component of advancing biomedical and public health research. To date, efforts to increase the ability to design and carry out pragmatic trials have largely focused on training researchers. To complement these efforts, we developed an interactive workshop tailored to meet the roles and responsibilities of program scientists at the National Cancer Institute-the leading cancer research funding agency in the USA. The objectives of the workshop were to improve the understanding of pragmatic trials and enhance the capacity to distinguish between elements that make a trial more pragmatic or more explanatory among key programmatic staff. To our knowledge, this is the first reported description of such a workshop.
    Main body: The workshop was developed to meet the needs of program scientists as researchers and stewards of research funds, which often includes promoting scientific initiatives, advising prospective applicants, collaborating with grantees, and creating training programs. The workshop consisted of presentations from researchers with expertise in the design and interpretation of trials across the explanatory-pragmatic continuum. Presentations were followed by interactive, small-group exercises to solidify participants' understanding of the purpose and conduct of these trials, which were tailored to attendees' areas of expertise across the cancer control continuum and designed to reflect their scope of work as program scientists at NCI. A total of 29 program scientists from the Division of Cancer Control and Population Sciences and the Division of Cancer Prevention participated; 19 completed a post-workshop evaluation. Attendees were very enthusiastic about the workshop: they reported improved knowledge, significant relevance of the material to their work, and increased interest in pragmatic trials across the cancer control continuum.
    Conclusion: Training program scientists at major biomedical research agencies who are responsible for developing funding opportunities and advising grantees is essential for increasing the quality and quantity of pragmatic trials. Together with workshops for other target audiences (e.g., academic researchers), this approach has the potential to shape the future of pragmatic trials and continue to generate more and better actionable evidence to guide decisions that are of critical importance to health care practitioners, policymakers, and patients.
    MeSH term(s) Capacity Building/methods ; Capacity Building/organization & administration ; Education/methods ; Education/organization & administration ; Humans ; National Cancer Institute (U.S.) ; Neoplasms/epidemiology ; Neoplasms/psychology ; Neoplasms/therapy ; Pragmatic Clinical Trials as Topic/methods ; Pragmatic Clinical Trials as Topic/standards ; Quality Improvement ; Research/classification ; Research/education ; Research/organization & administration ; Research Personnel/education ; Research Support as Topic ; United States
    Language English
    Publishing date 2019-12-27
    Publishing country England
    Document type Letter
    ZDB-ID 2040523-6
    ISSN 1745-6215 ; 1468-6694 ; 1745-6215
    ISSN (online) 1745-6215
    ISSN 1468-6694 ; 1745-6215
    DOI 10.1186/s13063-019-3934-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top